Jahangiri, A., Mahmoudian, M., Jalalizadeh, H., Shafiee, A. (2010). Paraoxonase Inhibition by Propranolol. Iranian Journal of Pharmaceutical Research, Volume 3(Number 3), 155-158. doi: 10.22037/ijpr.2010.593
A Jahangiri; M Mahmoudian; H Jalalizadeh; A Shafiee. "Paraoxonase Inhibition by Propranolol". Iranian Journal of Pharmaceutical Research, Volume 3, Number 3, 2010, 155-158. doi: 10.22037/ijpr.2010.593
Jahangiri, A., Mahmoudian, M., Jalalizadeh, H., Shafiee, A. (2010). 'Paraoxonase Inhibition by Propranolol', Iranian Journal of Pharmaceutical Research, Volume 3(Number 3), pp. 155-158. doi: 10.22037/ijpr.2010.593
Jahangiri, A., Mahmoudian, M., Jalalizadeh, H., Shafiee, A. Paraoxonase Inhibition by Propranolol. Iranian Journal of Pharmaceutical Research, 2010; Volume 3(Number 3): 155-158. doi: 10.22037/ijpr.2010.593
There are many evidences that human serum paraoxonase activity modifies plasma lipid profile and paraoxonase has an antiatherogenic property. Non-selective beta-blockers affect plasma lipid profile too, but they have atherogenic property when patients take these drugs in long term. In this study the effect of propranolol, a non-selective beta-blocker, on paraoxonase activity was investigated. Lineweaver-Burk and secondary plots were drawn and showed that propranolol is a mixed non-competitive inhibitor of paraoxonase.
Iranian Journal of Pharmaceutical
Research (2004) 3: 155-158
Received: December 2003
Accepted: May 2004
Copyright ? 2004 by School of Pharmacy
Shaheed Beheshti University of Medical Sciences and Health Services
Original Article
Paraoxonase Inhibition by Propranolol
Alireza Jahangiria, Masoud
Mahmoudianb, Hassan Jalalizadeha and Abbas Shafieea*
aDepartment
of Medicinal Chemistry and Pharmaceutical Sciences Research
Center, Faculty of Pharmacy, Tehran University of Medical
Sciences, Tehran, Iran. bDepartment of Pharmacology, Faculty of Medicine,
Iran University of Medical Sciences, Tehran, Iran
There are many evidences that human
serum paraoxonase activity modifies plasma lipid profile and
paraoxonase has an antiatherogenic property. Non-selective
beta-blockers affect plasma lipid profile too, but they have
atherogenic property when patients take these drugs in long
term. In this study the effect of propranolol, a non-selective
beta-blocker, on paraoxonase activity was investigated.
Lineweaver-Burk and secondary plots were drawn and showed that
propranolol is a mixed non-competitive inhibitor of
paraoxonase.
Human serum paraoxonase (PON1, EC 3.1.8.1)
is a Ca2+ dependent, 45 kDa glycoprotein that is
associated with high density lipoprotein (HDL). PON1 hydrolyses
organophosphates, insecticides and nerve gases. Although PON1
can offer protection against the toxicity of some
organophosphates, its physiological role is still not known.
However, evidence exists for a protective effect of PON1
against oxidative damage. It retards the oxidation of low
density lipoprotein (LDL), both in vivo and in vitro, by
hydrolyzing the lipid peroxides formed in plasma (1-4). It has
been suggested that PON1 is related to coronary heart disease
risk. PON1 activity was reported to be lower in subjects with
familial hypercholesterolemia, the disease that lead to the
development of atherosclerosis. PON1 activity is under genetic
and environmental regulation and appears to vary widely among
individuals and populations (5).
Beta-blockers are widely used to treat
cardiovascular diseases. It has been shown that non-selective
beta-blockers affect the concentration and oxidizability of
plasma lipids. They tend to increase triglycerides and LDL,
while decreasing the atheroprotective HDL (10). There is no
previous report on the effect of beta-blockers on PON1
activity. Propranolol is a well known non-selective
beta-blocker widely used in the treatment of arrhythmia, angina
and hypertension.
The aim of the present study was to
investigate whether propranolol, a non-selective beta-blocker
could affect PON1 activity.
Experimental
PON1 activity was measured
spectrophotometrically. PON1 hydrolyses paraoxon (substrate) in
the presence of Ca2+ and Na+ and as a result p-nitrophenol is liberated (11, 12). An Increase
in absorbance at 412 nm is related to PON1 activity. No
absorbance was observed in visible range for plasma itself.
Materials
Paraoxon was purchased from Sigma-Aldrich
chemie GmbH (Germany).
Propranolol was obtained from Tolid Daru
(Iran). Other chemical compounds were from Merck Co. (Germany).
UV absorbance was measured with a SHIMADZU 160-A
spectrophotometer. Serum was obtained from a fast, healthy,
non-smoker, male volunteer.
Solutions
Solution A: glycine/NaOH buffer (50 mM, pH=
10.0) containing 1.0 M NaCl and 1.0 mM CaCl2 was prepared.
Solutions B1-B6: Paraoxon was added to
solution A to reach final concentrations of2.5, 5.0, 7.5, 10,
12.5 and 15.0 mM respectively.
Solutions C1-C6: Propranolol (as the base)
was dissolved in methanol to prepare concentrations of 0.25,
0.5, 0.75, 1.0, 1.25 and 1.5 mM respectively.
Methods
PON1 activity measurement
Four hundred ml of a 1/5 prediluted serum sample with
distilled water, was added to 4.1 ml solution A and then 500 ml of one of the
solutions B1-B6 was added. The rate of paraoxon hydrolysis was
assessed by measuring liberation of p-nitrophenol at 412 nm at
25 C (e=
17000, pH=10.0). For subtraction of non-enzymatic hydrolysis,
blanks (samples without serum) were used. Enzyme activities
were expressed in international units (U) per milliliter of
serum. One U corresponds to the quantity of enzyme that
hydrolyses 1 mmol of substrate per minute at the given pH and
temperature.
Inhibition assay
1) Four hundred ml of a 1/5 prediluted
serum sample with distilled water, was added to 4.0 ml solution
A and then 100 ml one of the solutions C1-C6 was added. After 10 min incubation, 500 ml of solution B6
was added and the absorbance measured at 412 nm. 2) Four
hundred ml of a 1/5 prediluted serum sample was added to 4.0 ml
solution A followed by the addition of 100 ml of solution C2. After
10 min incubation, 500 ml of one of the solutions B1-B6 was added and
absorbance measured at 412 nm.
Results And Discussion
The enzyme kinetic (with and without
propranolol) has been shown as the Lineweaver-Burk plot in
figure 1. Figure 1 shows that propranolol is a mixed
non-competitive inhibitor of PON1. Hence the equation
describing the kinetics is a modified form of the
Lineweaver-Burk equation:
Secondary plots were drawn and shown in
figures 2-a and 2-b. PON1 kinetic parameters were calculated
(Km=0.4 mM, Vm=0.255 mol.min-1.ml-1 serum) and inhibition parameters were obtained
through Figures 2-a and 2-b (Ki=37 mm, aKi=KI=79 mM, a=2.13).
Based on the previous reports, PON1
activity is under genetic and environmental regulation.
Regarding the environmental parameters, it has been reported
that mice which had consumed red wine had less oxidized LDL,
presumably related to an enhanced serum PON1 activity in these
polyphenol-treated mice (6).
The inhibition of LDL oxidation by HDL is
due to the hydrolysis of lipid peroxidases and the resulting
inhibition of lipid peroxides appears to be, at least in part,
a function of the enzyme paraoxonase, which is a component of
HDL (2, 13). It has been shown that PON1 destroys the
multioxygenated molecules found in oxidized phosphatidycholine.
Furthermore, it has been demonstrated that inactivation of PON1
reduces the ability of HDL to inhibit LDL modification. It also
reduces the ability of HDL to inhibit monocytic-endothelial
interactions. They both appear to be important in the
inflammatory response of arterial wall cells, which promotes
atherogenesis (3). PON1 reduces mildly oxidized phospholipids
by eliminating oxidized derivatives of unsaturated fatty acids
(2, 3). It has also been shown that smoking is associated with
a reduced serum PON1 activity and concentration (7). However,
vitamins C and E intake are associated with an increased PON1
activity (8).
Serum PON1 activity is significantly
increased during treatment with simvastatin (9). These
evidences imply the importance of jointly considering
environmental factors that modify PON1 activity.
Overall, in this study we found that
propranolol, a well known non-selective beta-blocker, is a
mixed non-competitive human serum paraoxonase inhibitor. Thus,
it is possible that the use of propranolol could be influencing
PON1 activity and its effect on the concentration and
oxidizability of plasma lipids may be related to this property.
Acknowledgement
This work was partially supported by a
grant from Tehran University of Medical Sciences Research
council.
References
(1) Mackness MI, Arrol S and Durrington PN.
Paraoxonase prevents accumulation of lipoperoxides in
Low-density lipoproteins. FEBS
Letts. (1991) 286: 152- 4
(2) Mackness MI, Arrol S, Abbott CA and
Durrington PN. Protection of low-density lipoprotein against
oxidative modification by high-density lipoprotein associated
paraoxonase. Atherosclerosis (1993) 104: 129-35
(3) Watson AD, Berliner JA, Hama SY, La Du
BN, Fault KF, Fogelman AM and Navab M. Protective effect of
high density lipoprotein associated paraoxonase. Inhibition of
the biological activity of minimally oxidized low density
lipoprotein. J. Clin. Invest. (1995) 96: 2882-91
(4) Aviram M, Rosenblat M, Bisgaier CL,
Newton RS, Primo-Parmo SL and La Du BN. Paraoxonase inhibites
high-density lipoprotein oxidation and preserves its functions,
a possible peroxidative role for paraoxonase. J. Clin. Invest. (1998) 101: 1581-90
(5) Mackness B, Mackness MI, Durrington PN,
Arrol S, Evans AE, McMaster D, Ferriers J, Ruidavets JB,
Williams NR and Howard AN. Paraoxonase acitivity in two healthy
populations with differing rates of coronary heart disease. Eur. J. Clin. Invest. (2000) 30: 4-10
(6) Hayek T, Fuhrman B, Vaya J, Rosenblat
M, Belinky P, Coleman R, Elis A and Aviram M. Reduced
progression of atherosclerosis in apolipoprotein E-deficient
mice following consumption of red wine, or its polyphenols
quercetin or cathechin is associated with reduced
susceptibility of LDL to oxidation and aggregation. Arterioscler. Thromb. Vasc. Biol. (1997) 17: 2744-52
(7) James RW, Leviev I and Righetti A.
Smoking is associated with reduced serum paraoxanase activity
and concentration in patients with coronary artery disease. Circulation (2000)
101: 2252-7
(8) Jarvik GP, Trevanian N, Mckinstry LA,
Wani R, Brophy VH, Richter RJ, Schellenberg G D, Heagerty PJ,
Hatsukami TS and Furlong CE. Vitamin C and E intake is
associated with increased paraoxonase activity. Arterioscler. Thromb. Vasc. Biol. (2002) 22: 1329-33
(9) Tomas M, Senti M, Garcia-Faria F, Vila
J, Torrents A, Covas M and Marrugat J. Effect of simvastatin
therapy on paraoxonase activity and related lipoproteins in
familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. (2000) 2: 2113-9
(10) Superko HR, Haskell WL and Krauss RM.
Association of lipoprotein subclass distribution with use of
slective and non-selective beta-blocker medication in patients
with coronary heart disease. Atherosclerosis (1993) 101: 1-8
(11) Dantoine TF, Debord J, Chames JP,
Marquet P, Marle L, Lachatre G and Leroux-Robert C. Decrease of
serum paraoxonase activity in chronic renal failure. J. Am. Soc. Nephrol. (1998) 9: 2082-88
(12) Mackness B, Durrington PN and Mackness
MI. Human Serum Paraoxonase. Gen.
Pharmac. (1998) 31: 329-36
(13) Blatter M, James RW, Messmer S, Barja F
and Pometta D. Identification of a distinct human high-density
lipoprotein subspecies defined by a lipoprotein-associated
protein, K-45: identity of K-45 with paraoxonase. Eur. J. Biochem. (1993) 211: 871-879
Top